LYEL - Lyell Immunopharma Shares Plunge On One Patient Death In CAR-T Cell Therapy Cancer Trial | Benzinga
Lyell Immunopharma Inc (NASDAQ:LYEL) shares are trading lower on Wednesday on a heavy session volume of 5.79 million shares as per data from Benzinga Pro.
The company released initial clinical and translational data from its Phase 1 trial of LYL797, its first-generation reprogrammed ROR1 CAR T?cell product candidate enhanced with proprietary anti-exhaustion technology.
This initial dataset of 20 treated patients includes 16 patients with TNBC and four patients with non-small cell lung cancer and demonstrated dose-dependent antitumor clinical activity and ...